Social Workers Are Underutilized in Oncologic Pain Management
Expertise in the use of nonpharmacologic pain management techniques and therapies allow masters-prepared social workers to be an integral member of a multidisciplinary cancer care team.
Side-Effect Management
Larger Sample Size Needed to Determine Benefit of Olanzapine for Chronic Nausea, Vomiting in Advanced Cancer
Although olanzapine shows promise as a treatment for chronic nausea and vomiting in patients with advanced cancer, larger studies are needed.
Hemophagocytic Lymphohistiocytosis and Inflammatory Bowel Disease
Investigators aimed to characterize HLH in patients with moderate-to-severe inflammatory bowel disease.
New-Onset Type 2 Diabetes as a Potential Biomarker in Pancreatic Cancer
The study results suggest that patients with weight loss after age 50 years in the context of new-onset type 2 diabetes may be good candidates for pancreatic cancer screening.
Chemotherapy-Induced Nausea and Vomiting Prophylaxis
The ASCO guideline provides updated recommendations for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) based on the emetic risk of the treatment regimen.
Transdermal Granisetron an Option for High-Risk CINV, Poor Adherence to Oral Antiemetics
A prospective study demonstrated this treatment is an option for patients undergoing chemoradiation for gynecologic cancers who are at risk of late-onset CINV or noncompliance with oral therapy.
Aromatherapy With Peppermint Essential Oil May Help Alleviate Nausea Associated With Chemotherapy
A randomized study determined the efficacy of adding peppermint essential oil to a cool wash cloth to ease nausea associated with chemotherapy.
Approach Immune Checkpoint Inhibitor Rechallenge Cautiously After Initial Immune-Related Adverse Events
Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.
Pedmark Receives Priority Review for Prevention of Cisplatin-Induced Ototoxicity
The application is supported by data from 2 pivotal open-label, randomized phase 3 trials (SIOPEL 6 and ACCL0431), which compared the efficacy of sodium thiosulfate plus cisplatin to cisplatin alone for the prevention of cisplatin-induced hearing loss.
Psoriasis Linked to Increased Risk for Developing Cancer
Increased risk particularly seen with keratinocyte cancer and lymphomas.
Next post in General Oncology
